Trial Profile
A Phase I Open-Label Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single Intravitreal and Subconjunctival Doses of Palomid 529 in Patients With Advanced Neovascular Age-Related Macular Degeneration (AMD)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs RES 529 (Primary)
- Indications Age-related macular degeneration; Choroidal neovascularisation
- Focus Adverse reactions
- Sponsors Paloma Pharmaceuticals
- 15 May 2014 New trial record